PP.05.33: LIRAGLUTIDE DECREASES MICROALBUMINURIA AND BLOOD PRESSURE IN HYPERTENSIVE OBESE PATIENTS WITH TYPE 2 DIABETES. (June 2015) - Garcia, J.C. Fernandez
Abstract : Objective: Liraglutide, a novel glucagon-like peptide-1 receptor agonist drug, has been associated with blood pressure decrease, but few reports exist about its role in albuminuria. In this study, we aimed to evaluate if liraglutide possesses any potential efficacy on albuminuria reduction in hypertensive obese patients with type 2 diabetes mellitus (T2DM). Design and method: Retrospective observational study, including obese hypertensive patients with T2DM and microalbuminuria who were started on liraglutide (0.6 mg/daily first week, 1.2 mg/daily afterwards). Microalbuminuria was defined as present if albumin/creatinine ratio was 30–299 mg/dl. During the study period, no modifications in antihypertensive therapy were done. Baseline and 4 months evaluations were performed Results: 17 obese (mean weight 104.8 ± 17 kg, mean BMI 40.3 ± 4.3 kg/m2) hypertensive (mean number of antihypertensives 1.86 ± 0.6) T2DM patients (mean age 50.3 ± 9.7 years, women 82.4%) were included in the study. Mean albuminuria levels were 56 ± 26.3 mg/dl and baseline eGFR was 93.9 ± 18 ml/min/1.73m2. Also, mean baseline HbA1c was 8.6 ± 1.3%, mean baseline systolic blood pressure (SBP) levels were 150.5 ± 17.7 mmHg and mean diastolic blood pressure (DBP) levels were 89.4 ± 10 mmHg. After 18 ± 4 weeks of average follow-up, albuminuria decreased 21.36 mg/dl (p = 0.04), eGFR remained unchanged, SBP was reduced 10 mmHg (p = 0.04), DBP decreased 3.2 mmHg (p = 0.23), body weight decreased 4.9 kg (p = 0.015) and HbA1c was reduced 1% (p < 0.01). Also, in 12 patients (70.5% out of total) microalbuminuria was restored to normoalbuminuria (p < 0.05). Conclusions: Liraglutide decreases albuminuria and lowers blood pressure in hypertensive obese patients with T2DM. Further clinical trials are needed to confirm the antiproteinuric effect of liraglutide.